Fluorometholone Acetate

Summary

Fluorometholone Acetate (CHEMBL1201064) is an approved small-molecule anti-inflammatory drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 3
• Chemistry: 418.5 Da · C24H31FO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201064
Name	Fluorometholone Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	240767
ChEBI	CHEBI:78354
Molecular formula	C24H31FO5
Molecular weight	418.5
InChIKey	YRFXGQHBPBMFHW-SBTZIJSASA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)OC(=O)C

IUPAC name: [(6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11-hydroxy-6,10,13-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate

ChEBI definition: A steroid ester resulting from the formal condensation of the 17-hydroxy function of fluorometholone with acetic acid. Used in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Pharmacological roles (ChEBI): anti-inflammatory drug.

Also known as: Flarex, Fluorometholone acetate, NSC-47438, U-17,323, U-17323, FLUOROMETHOLONE ACETATE, SID100431, Fluorometholone Acetate

Patent coverage: 1,116 distinct patent families (4,013 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07553455	PHASE4	ENROLLING_BY_INVITATION	Vevye + Flarex Combination Therapy for Dry Eye
NCT01024322	Not specified	TERMINATED	Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
NCT01189864	Not specified	TERMINATED	Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).